Daewoong Pharmaceutical Launches 'Mucotra Sustained-Release Tablets' for Gastritis Treatment... Reduces Dosage Frequency and Size

Improved New Drug Containing Revaprazan

Mucotra Sustained-Release Tablets 150mg (Photo by Daewoong Pharmaceutical)

[Asia Economy Reporter Kim Ji-hee] Daewoong Pharmaceutical is launching an improved new drug containing the active ingredient rebamipide, designed to enhance medication convenience, and is expanding its market presence.

On the 5th, Daewoong Pharmaceutical announced the release of ‘Mucotra Sustained-Release Tablets 150mg,’ a sustained-release formulation of rebamipide used for gastritis treatment. This product can improve gastric mucosal lesions (erosion, bleeding, redness, edema) in both acute and chronic gastritis with twice-daily dosing regardless of meals. While the previously released rebamipide immediate-release tablets required three doses per day, the sustained-release tablets reduce the dosing frequency to twice daily.

Mucotra Sustained-Release Tablets 150mg were co-developed by Daewoong Pharmaceutical in collaboration with Yuhan Corporation, GC Green Cross, and Daewon Pharmaceutical. Phase 3 clinical trials confirmed similar gastritis improvement effects and safety compared to the immediate-release tablets. The tablets are also made smaller than 1 cm, similar to the immediate-release tablets, enhancing medication convenience.

Lee Chang-jae, Vice President of Daewoong Pharmaceutical, stated, “With the launch of Mucotra Sustained-Release Tablets, we expect to improve medication adherence for many patients and reduce their treatment burden with an economical drug price. Daewoong Pharmaceutical will continue to do its best to provide various treatment options based on excellent product quality and a differentiated four-step verified marketing strategy.”

This content was produced with the assistance of AI translation services.